Terray Therapeutics

About Terray Therapeutics

Terray Therapeutics is pioneering a chemistry-first, AI-native approach to small molecule drug discovery through its EMMI (Experimentation Meets Machine Intelligence) platform. The company has invented proprietary hardware, built massive proprietary datasets, and designed custom AI models to fundamentally reimagine how drugs are discovered. At the core of Terray's approach is a patented ultra-dense microarray technology that has generated over 17 billion unique measurements, growing by 1 billion every quarter—creating a proprietary dataset 50x larger than all public chemistry data. This experimental foundation feeds COATI, Terray's foundation model trained on 1 billion molecules, which enables the company to explore dark areas of chemical space that traditional methods cannot access. The EMMI platform integrates generative AI for molecule design, predictive models including TerraBind for binding affinity prediction, and automated experimentation that closes the loop between design and testing. Terray has successfully screened over 90% of difficult targets to yield unique chemistry starting points and has progressed 8 AI-driven programs for undruggable targets in the past 4 years, operating 2x faster than traditional approaches. The company serves pharmaceutical and biotech partners while building its own internal pipeline, focusing on targets previously considered undruggable. Terray's multidisciplinary team combines expertise in chemistry, biology, machine learning, and automation engineering to tackle the hardest problems in drug discovery.

Clinical Focus

Medical conditions and clinical areas addressed by Terray Therapeutics.

Who It Serves

Milestones & Awards

Key Partnerships

Social & Media